NCT05836558

Brief Summary

Mitral regurgitation (MR) is a disease affecting the mitral valve that it causes a volumetric and pressure overload in the left chambers due to the leak of the unidirectionality normally guaranteed by the heart valve system. The gold standard for severe mitral regurgitation is currently surgical mitral valve repair (PLM) using longitudinal median sternotomy to expose the heart Since the mid-1990s, the right mini-thoracotomy, ie a surgical access with cut in the 3rd or 4th intercostal space that would allow to reduce the size of the surgical site making it less traumatic and more aesthetic, addressing mainly a young target population. Since the 2000s this method has spread more and more, expanding all over the world and spreading especially in the United States and Germany. This method has been progressively used in the treatment of the whole mitral valve surgery starting from valve repair up to prosthetic replacements. Mitral valve repair through minimally invasive access in degenerative pathology has made it possible to obtain excellent long-term results, with low recurrence rates of regurgitation. In our center the results on the first 48 patients have been published in 2005 by Lapenna et al. Over the years this method has been adopted in thousands of patients worldwide, however the data present in the literature they stop at a follow-up of about 10 years. In 2017 De Bonis et al. of the San Raffaele Hospital have published the outcome of a particular subgroup of patients (bileaflet prolapse) treated with minimally invasive access, comparing them with as many subjects subjected to the same method of mitral repair ("edge-to-edge technique or Alfieri stitch"), obtaining superimposable long-term results (about 14 years old). The goal of the present study is to analyze very long-lasting results in patients treated with mitral valve surgery with access in right mini-thoractotomy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
127

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 5, 2019

Completed
10 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 15, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 15, 2019

Completed
3.3 years until next milestone

First Submitted

Initial submission to the registry

January 27, 2023

Completed
3 months until next milestone

First Posted

Study publicly available on registry

May 1, 2023

Completed
Last Updated

May 1, 2023

Status Verified

April 1, 2023

Enrollment Period

10 days

First QC Date

January 27, 2023

Last Update Submit

April 28, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Mortality

    through study completion, a minimum of 16 years

Secondary Outcomes (1)

  • Reintervention

    through study completion, a minimum of 16 years

Interventions

reparative surgery of the mitral valve accessing heart via an incision in the right 3rd or 4th intercostal space.

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients operated with mitral valve repair in right minithoracotomy to treat degenerative mitral valve disease

You may qualify if:

  • patients with degenerative mitral regurgitation
  • patients treated with mitral valve repair in right minithoracotomy

You may not qualify if:

  • median sternotomy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

IRCCS Ospedale San Raffaele

Milan, 20132, Italy

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Chief of Cardiac Surgery of Advanced and Research Therapies

Study Record Dates

First Submitted

January 27, 2023

First Posted

May 1, 2023

Study Start

October 5, 2019

Primary Completion

October 15, 2019

Study Completion

October 15, 2019

Last Updated

May 1, 2023

Record last verified: 2023-04

Locations